Cross Q&A: Team Memorial Sloan Kettering

News
Video

The Dana-Farber team puts Memorial Sloan Kettering to the test and questions the panel on the presented abstracts.

Recent Videos
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis

Bezuclastinib Demonstrates Improved Symptoms in Systemic Mastocytosis

Darlene Dobkowski, MA
December 16th 2024
Article

Median duration on bezuclastinib was 56 weeks vs 40 weeks for placebo in non-advanced systemic mastocytosis, the phase 2 Summit trial reported.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies

Improved OS in Leukemia Elicited by cBTK and BCL2 inhibitors and anti-CD20 Antibodies

Jordyn Sava
December 12th 2024
Article

Data shown at ASH 2024 demonstrated higher OS rates with anti-CD20 antibodies in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Management and Prevention of AEs Associated With Ponatinib Improved

Management and Prevention of AEs Associated With Ponatinib Improved

Jonah Feldman
December 12th 2024
Article
Positive PFS and EFS Outcomes Were Elicited by Pirobrutinib in CLL and SLL

Positive PFS and EFS Outcomes Were Elicited by Pirobrutinib in CLL and SLL

Tony Berberabe, MPH
December 10th 2024
Article

Pirobrutinib sustained BTK inhibition and improved progression-free survival in patients with CLL and SLL, data from the phase 3 BRUIN CLL-321 trial showed.